- Mycenax Biotech Inc. has entered into a strategic alliance with Japan-based SPERA PHARMA Inc. to provide integrated antibody-drug conjugate (ADC) and bioconjugate solutions.
- The collaboration combines expertise in biologics, CMC, and high-potent fill-finish services to offer global clients a turnkey contract manufacturing platform.
Mycenax Biotech Inc. has announced a strategic alliance with SPERA PHARMA Inc., a Japan-based contract development and manufacturing organisation (CDMO). The partnership aims to deliver an integrated solution for antibody-drug conjugates (ADCs) and bioconjugates.
The collaboration will cover linker and payload synthesis, drug substance production, formulation, and aseptic fill-finish. According to the companies, the combined platform is designed to accelerate time-to-market for biopharmaceutical firms through a cost-effective and streamlined development pathway.
Founded in 2017 as a spin-off from Takeda Pharmaceutical Company’s CMC Research Division, SPERA PHARMA is recognised for its expertise in process chemistry, formulation, analytical development, and GMP-compliant aseptic manufacturing. The company is considered one of Japan’s leading CDMOs.
Mycenax, based in Taiwan, is a global biologics CDMO with regulatory approvals from agencies including EMA, PMDA, and Health Canada. The company previously partnered with KriSan Biotech in 2022 to expand its ADC technology platform, adding site-specific conjugation and novel linker designs.
By combining these capabilities, Mycenax and SPERA PHARMA are offering a scalable, end-to-end ADC development and manufacturing service intended to provide global clients with speed, flexibility, and technical strength.
